MRNA vs XFOR
Head-to-Head Stock Analysis & Investment Rating
Last Updated: Oct 23, 2026
MRNA
XFOR
Investment Advisor Scores
XFOR
AI Analyst Insights
Detailed Metrics Comparison
| Metric | MRNA | XFOR | Winner |
|---|---|---|---|
|
Valuation
Lower P/E and PEG ratios suggest a stock may be undervalued relative to earnings and growth. Value investors prefer lower multiples. |
|||
| Forward P/E | 23.0415 | 0 | Tie |
| PEG Ratio | 0 | 0 | Tie |
|
Growth
Higher revenue and earnings growth rates indicate a company is expanding faster. Strong growth often justifies premium valuations. |
|||
| Revenue Growth | 2.1% | 346.3% | XFOR |
| Earnings Growth | -85.1% | 0.0% | XFOR |
|
Quality & Profitability
Higher Tradestie Score and profit margins reveal how efficiently a company operates. Strong profitability indicates competitive advantages. |
|||
| Tradestie Score | 35.2/100 | 40.7/100 | XFOR |
| Profit Margin | -141.4% | 0.0% | XFOR |
|
Risk Profile
Lower Beta and Implied Volatility values indicate reduced market risk. Conservative investors favor stocks with less price volatility. |
|||
| Beta | 1.00 | 1.00 | Tie |
|
Sentiment
AI Recommendation reflects overall analyst and proprietary sentiment. Stronger recommendations signal higher conviction. |
|||
| AI Recommendation | AVOID NEW MONEY | HOLD | XFOR |
Relative Price Performance (Last 90 Days)
Current Technical Phase
MRNA
MarkupPrice above SMA50, rising 50-day trend (56.8% over 20 days), RSI 51
XFOR
NeutralMixed signals - no dominant trend phase, RSI 56
Fundamentals Snapshot
| Metric | MRNA | XFOR |
|---|---|---|
| Market Cap | — | — |
| Forward P/E | -42.4 | -4.2 |
| Trailing P/E | — | 150.5 |
| Revenue (TTM) | — | — |
| Revenue Growth | 0.0% | 3.5% |
| Gross Margin | -0.7% | 0.8% |
| Operating Margin | -5.6% | -1.9% |
| EPS | -8.10 | 0.02 |
| Dividend Yield | — | — |